GSK (NYSE: GSK) details June share buybacks and updated voting rights

Rhea-AI Filing Summary

GSK plc reports purchases of its own ordinary shares between 15 and 19 June 2026 under its existing share buyback programme, executed through Citigroup Global Markets Limited. Daily purchases ranged from 209,874 to 245,840 shares, at volume-weighted average prices between 1,934.67 and 1,971.11 GBp per share.

The purchased shares will be held as treasury shares. Since 11 May 2026, GSK has bought 8,448,125 ordinary shares. After these transactions, it holds 269,826,411 shares in treasury and has 4,046,440,349 ordinary shares in issue, which is also the total number of voting rights.

The company states that, following these purchases, 6.67 per cent of voting rights are attributable to ordinary shares held in treasury, which shareholders can use as the denominator for disclosure calculations under UK transparency rules.

Key Figures

Shares bought 15 June 2026: 215,325 shares VWAP 15 June 2026: 1,971.11 GBp/share Largest daily June purchase: 245,840 shares +4 more

7 metrics

Shares bought 15 June 2026 215,325 shares Aggregate number of ordinary shares purchased on 15 June 2026

VWAP 15 June 2026 1,971.11 GBp/share Volume-weighted average price paid per share on 15 June 2026

Largest daily June purchase 245,840 shares Aggregate number of shares purchased on 18 June 2026

Shares bought since 11 May 2026 8,448,125 shares Total ordinary shares repurchased under the buyback programme

Treasury share balance 269,826,411 shares Ordinary shares held in treasury after the reported purchases

Shares in issue 4,046,440,349 shares Ordinary shares in issue excluding treasury; equals total voting rights

Treasury voting rights percentage 6.67 per cent Percentage of voting rights attributable to treasury-held ordinary shares

Key Terms

Treasury shares, buyback programme, Market Abuse Regulation, Disclosure Guidance and Transparency Rules, +1 more

5 terms

Treasury shares financial

"The purchased shares will be held as Treasury shares."

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

buyback programme financial

"Such share purchases form part of the Company's existing buyback programme"

Market Abuse Regulation regulatory

"In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014"

Market abuse regulation consists of laws and rules designed to prevent dishonest or manipulative practices in financial markets. It aims to ensure fair and transparent trading, so investors can trust that markets operate honestly, much like rules that keep a game fair. By reducing unfair advantages, it helps protect investor confidence and promotes healthy, efficient markets.

Disclosure Guidance and Transparency Rules regulatory

"under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules."

Disclosure guidance and transparency rules are the standards and regulations that require companies to share clear, timely information about their finances, risks, operations and material events. They matter to investors because consistent, honest reporting is like a car’s dashboard — it reveals the data you need to judge safety and performance and make informed buying or selling decisions. Strong disclosure reduces surprises and helps keep markets fair and efficient.

voting rights financial

"the total number of voting rights in the Company will be 4,046,440,349."

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Transaction in own shares

GSK plc (the "Company") announces today acting through Citigroup Global Markets Limited (the "Broker"), it has purchased the following number of the Company's ordinary shares of 31¼ pence each.

Date of purchase	Aggregate number of ordinary shares of 31 ¼ pence each purchased	Lowest price paid per share (GBp)	Highest price paid per share (GBp)	Volume weighted average price paid per share (GBp)
15 June 2026	215,325	1,955.50	1,988.50	1,971.11
16 June 2026	214,000	1,940.50	1,968.00	1,954.16
17 June 2026	209,874	1,936.00	1,973.50	1,954.80
18 June 2026	245,840	1,906.00	1,978.00	1,942.62
19 June 2026	216,850	1,918.00	1,942.50	1,934.67

The purchased shares will be held as Treasury shares.

Such share purchases form part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 8 May 2026, as announced on 11 May 2026.  Since 11 May 2026 the Company has purchased 8,448,125 ordinary shares.

Following the above purchases, the Company will hold 269,826,411 ordinary shares in treasury and have 4,046,440,349 ordinary shares in issue (excluding Treasury shares).

Following the above purchases, the total number of voting rights in the Company will be 4,046,440,349. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Company confirms that, in accordance with DTR 5.5.1R, following the above purchases the percentage of voting rights attributable to the ordinary shares held in treasury is 6.67 per cent.

In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended, a full breakdown of the individual purchases of ordinary shares made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) is set out in the Schedule to this announcement, available via the link below:

http://www.rns-pdf.londonstockexchange.com/rns/2177J_1-2026-6-22.pdf

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

GSK enquiries
Media:	Tim Foley	+44 (0) 20 8047 5502	(London)
	Kathleen Quinn	+1 202 603 5003	(Washington DC)
Investor Relations:	Constantin Fest	+44 (0) 7831 826525	(London)
	James Dodwell	+44 (0) 20 8047 2406	(London)
	Mick Readey	+44 (0) 7990 339653	(London)
	Steph Mountifield	+44 (0) 7796 707505	(London)
	Sam Piper	+44 (0) 7824 525779	(London)
	Jeff McLaughlin	+1 215 751 7002	(Philadelphia)
	Frannie DeFranco	+1 215 751 3126	(Philadelphia)

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025, and GSK's Q1 Results for 2026.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: June 22, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What share buybacks did GSK (GSK) report for June 15–19, 2026?

GSK reported daily repurchases of its own ordinary shares from 15–19 June 2026. Daily volumes ranged from 209,874 to 245,840 shares, with volume-weighted average prices between 1,934.67 GBp and 1,971.11 GBp per share under its existing buyback programme.

How many GSK (GSK) shares have been repurchased since 11 May 2026?

Since 11 May 2026, GSK has repurchased 8,448,125 ordinary shares. These purchases form part of the company’s existing share buyback programme and are being executed under a non-discretionary agreement with Citigroup Global Markets Limited acting as broker.

How many GSK (GSK) shares are held in treasury after these buybacks?

After the reported purchases, GSK holds 269,826,411 ordinary shares in treasury. These shares are not counted as outstanding for voting purposes but do affect the percentage of voting rights attributable to treasury holdings under UK disclosure rules.

What is GSK’s (GSK) total number of voting rights after the June 2026 buybacks?

Following the June 2026 buybacks, GSK’s total number of voting rights is 4,046,440,349. Shareholders may use this figure as the denominator when assessing whether they must notify interests or changes under the Financial Conduct Authority’s transparency rules.

What percentage of GSK (GSK) voting rights is held in treasury shares?

GSK confirms that 6.67 per cent of its voting rights are attributable to ordinary shares held in treasury. This percentage is calculated after the latest share repurchases and is relevant for investors tracking significant shareholdings and disclosure thresholds.

Which broker executed GSK’s (GSK) June 2026 share repurchases?

The June 2026 share repurchases were executed by Citigroup Global Markets Limited. GSK states the trades were carried out under a non-discretionary agreement with this broker, with purchases made on the London Stock Exchange and CBOE Europe’s CHIX and BATE order books.